Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

(2021) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

(2020) Ulf Landmesser et al.   CARDIOVASCULAR RESEARCH

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies

(2020) Julia Brandts et al.   CURRENT OPINION IN LIPIDOLOGY

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

(2019) Connie B. Newman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

(2019) Guy De Backer et al.   ATHEROSCLEROSIS

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Inclisiran—New hope in the management of lipid disorders?

(2019) Krzysztof Dyrbuś et al.   Journal of Clinical Lipidology

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

(2019) R. Scott Wright et al.   MAYO CLINIC PROCEEDINGS

PCSK9 inhibitors in clinical practice: Expectations and reality

(2018) Željko Reiner   ATHEROSCLEROSIS

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1

(2018) Kausik K. Ray et al.   CIRCULATION

Inclisiran for the treatment of dyslipidemia

(2018) Toshiyuki Nishikido et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis

(2018) Gino A Vena et al.   Therapeutics and Clinical Risk Management

Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs

(2017) Anastasia Khvorova   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

(2016) Ž. Reiner et al.   ATHEROSCLEROSIS

Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients

(2016) Anselm K. Gitt et al.   ATHEROSCLEROSIS

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2016) Todd J. Anderson et al.   CANADIAN JOURNAL OF CARDIOLOGY

Adverse Effects of Statins - Myths and Reality

(2015) Iveta Simic et al.   CURRENT PHARMACEUTICAL DESIGN

Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators

(2015) Ulrike Flierl et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA